Spire Healthcare Group (LSE:SPI) Stock Still Looks Undervalued Against Its Sales Base

Spire Healthcare Group shares have posted a strong year to date return, which puts a fresh spotlight on whether the current £2.49 price makes sense when set against the revenue the business generates. With the spotlight firmly on its sales base rather than earnings or cash flows, the key issue is how much investors are really paying for each pound of Spire Healthcare Group's turnover.

• The stock is up 47.3% year to date, which raises the question of whether the move is backed by changes in how the market values the company's income from its hospitals and related services.

• The group's model is closely tied to occupancy levels, procedure volumes and case mix, so expectations for how these feed into future sales can heavily influence what investors are willing to pay today.

• The analysts covering Spire Healthcare Group have run their own numbers. See what analysts think Spire Healthcare Group's shares could be worth .

The issue now is whether the current share price is appropriately supported by Spire Healthcare Group's sales when judged against the Fair Ratio benchmark.

If you want more context on whether Spire Healthcare Group's £2.49 share price lines up with its sales, it can help to compare it against other companies screened for 12 high quality undervalued stocks

Is Spire Healthcare Group a Bargain on Sales?

For Spire Healthcare Group, a P/S multiple fits well because investors often focus on revenue capacity in hospital operators where earnings can be shaped by accounting and one off items.

On this lens, the stock trades on a P/S of 0.6x, which is lower than both the wider Healthcare sector on 1.3x and the peer group on about 2.1x. The Fair Ratio framework, which blends factors like growth profile, profitability, size and sector risk, points to a higher multiple than the market currently assigns. That places Spire Healthcare Group at a discount on this metric, with the price implying less value per pound of sales than the model suggests.

For you as a shareholder or potential buyer, the key question is whether Spire Healthcare Group can keep converting this revenue base into sustainable cash generation that justifies any closing of that gap. If the business model and balance sheet risks feel acceptable, a low P/S compared with this Fair Ratio can indicate underpriced turnover rather than weak revenue quality. Explore the numbers behind Spire Healthcare Group's P/S valuation .

The Spire Healthcare Group Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the valuation puzzle for Spire Healthcare Group leaves off, by spelling out which paths for growth, margins and earnings would need to hold for the shares to be worth materially more or less than today's price, and they sit on the platform's Community page. Rather than relying on a single multiple or one model output, each narrative sets out the assumptions behind its fair value so you can compare them against the company's actual results as they are reported.